CPAP Intervention as an Add-On Treatment to Lipid-Lowering Medication in Coronary Artery Disease Patients with Obstructive Sleep Apnea in the RICCADSA Trial

Dyslipidaemia is a well-known risk factor for coronary artery disease (CAD), and reducing lipid levels is essential for secondary prevention in management of these high-risk individuals. Dyslipidaemia is common also in patients with obstructive sleep apnea (OSA). Continuous positive airway pressure...

Descripción completa

Detalles Bibliográficos
Autores principales: Celik, Yeliz, Balcan, Baran, Peker, Yüksel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745784/
https://www.ncbi.nlm.nih.gov/pubmed/35012012
http://dx.doi.org/10.3390/jcm11010273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745784/
https://www.ncbi.nlm.nih.gov/pubmed/35012012
http://dx.doi.org/10.3390/jcm11010273

Ejemplares similares